Claus Lohman Brasen

Dr. Claus Lohman Brasen

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2024 in JBI Evidence Synthesis
Verified
Journal Article
Open access
EAEline Sandvig Andersen
Eline Sandvig Andersen
JBJohan Baden Birk-Korch
Johan Baden Birk-Korch
RHRasmus Søgaard Hansen
Rasmus Søgaard Hansen
LFLine Haugaard Fly
Line Haugaard Fly
RRRichard Röttger
Richard Röttger
JMJonna Madsen
Jonna Madsen
Objective: The objective of this review was to provide an overview of the diverse methods described, tested, or implemented for monitoring performance of clinical artificial intelligence (AI) systems, while also summarizing the arguments given for or against these methods. Introduction: The integration of AI in clinical decision-making is steadily growing. Performances of AI systems evolve over time, necessitating ongoing performance monitoring. However, the evidence on specific monitoring methods is sparse and heterogeneous. Thus, an overview of the evidence on this topic is warranted to guide further research on clinical AI monitoring. Inclusion criteria: We included publications detailing metrics or statistical processes employed in systematic, continuous, or repeated initiatives aimed at evaluating or predicting the clinical performance of AI models with direct implications for patient management in health care. No limitations on language or publication date were enforced. Methods: We performed systematic database searches in MEDLINE (Ovid), Embase (Ovid), Scopus, and ProQuest Dissertations and Theses Global, supplemented by backward and forward citation searches and gray literature searches. Two or more independent reviewers conducted title and abstract screening, full-text evaluation, and data extraction using a tool developed by the authors. During extraction, the methods identified were divided into subcategories. The results are presented narratively and summarized in tables and graphs. Results: Thirty-nine sources of evidence were included in the review, with the most abundant source types being opinion papers/narrative reviews (33%) and simulation studies (33%). One guideline on the topic was identified, offering limited guidance on specific metrics and statistical methods. The number of sources included increased year by year, with almost 4 times as many sources included in 2023 compared with 2019. The most commonly reported performance metrics were traditional metrics from the medical literature, including area under the receiver operating characteristics curve (AUROC), sensitivity, specificity, and predictive values, although few arguments were given supporting these choices. Some studies reported on metrics and statistical processing specifically designed to monitor clinical AI. Conclusion: This review provides a summary of the methods described for monitoring AI in health care. It reveals a relative scarcity of evidence and guidance for specific practical implementation of performance monitoring of clinical AI. This underscores the imperative for further research, discussion, and guidance regarding the specifics of implementing monitoring for clinical AI. The steady increase in the number of relevant sources published per year suggests that this area of research is gaining increased focus, and the amount of evidence and guidance available will likely increase significantly over the coming years. Review registration: Open Science Framework https://osf.io/afkrn

23 June 2021 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
CBClaus Lohman Brasen
Claus Lohman Brasen
HCHenry Christensen
Henry Christensen
DODorte A. Olsen
Dorte A. Olsen
SKSøren Kahns
Søren Kahns
RARikke F. Andersen
Rikke F. Andersen
IBIvan Brandslund
Ivan Brandslund
Objectives: We hypothesized that the amount of antigen produced in the body during a COVID-19 infection might differ between patients, and that maximum concentrations would predict the degree of both inflammation and outcome for patients. Methods: Eighty-four hospitalized and SARS-CoV-2 PCR swab-positive patients, were followed with blood sampling every day until discharge or death. A total of 444 serial EDTA plasma samples were analyzed for a range of biomarkers: SARS-CoV-2 nuclear antigen and RNA concentration, complement activation as well as several inflammatory markers, and KL-6 as a lung marker. The patients were divided into outcome groups depending on need of respiratory support and death/survival. Results: Circulating SARS-CoV-2 nuclear antigen levels were above the detection limit in blood in 65 out of 84 COVID-19 PCR swab-positive patients on day one of hospitalization, as was viral RNA in plasma in 30 out of 84. In all patients, complete antigen clearance was observed within 24 days. There were definite statistically significant differences between the groups depending on their biomarkers, showing that the concentrations of virus RNA and antigen were correlated to the inflammatory biomarker levels, respiratory treatment and death. Conclusions: Viral antigen is cleared in parallel with the virus RNA levels. The levels of antigens and SARS-CoV-2 RNA in the blood correlates with the level of IL-6, inflammation, respiratory failure and death. We propose that the antigens levels together with RNA in blood can be used to predict the severity of disease, outcome, and the clearance of the virus from the body.

13 February 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MHMathias Amdi Hertz
Mathias Amdi Hertz
IJIsik Somuncu Johansen
Isik Somuncu Johansen
FRFlemming S. Rosenvinge
Flemming S. Rosenvinge
CBClaus Lohman Brasen
Claus Lohman Brasen
EAEline Sandvig Andersen
Eline Sandvig Andersen
HSHelene Skjøt-Arkil
Helene Skjøt-Arkil
Urinary tract infections (UTIs) are a leading infectious cause of emergency department admission. Early UTI diagnosis is challenging, and a faster, preferably point-of-care urine analysis is necessary. We aimed to evaluate the diagnostic accuracy of urine flow cytometry (UFC) and urine dipstick analysis (UDA) in identifying bacteriuria and UTIs. This study included adults suspected of an infection admitted to three Danish emergency departments. UFC and UDA were the index tests, and urine culture and an expert panel diagnosis were the reference tests. We used logistic regression and receiver operator characteristics curves to find each test’s optimal model and cut-off. We enrolled 966 patients and performed urine cultures on 786. Urine culture was positive in 337, and 200 patients were diagnosed with a UTI. The UFC model ruled out bacteriuria in 10.9% with a negative predictive value (NPV) of 94.6% and ruled out UTI in 38.6% with an NPV of 97.0%. UDA ruled out bacteriuria in 52.1% with an NPV of 79.2% and UTI in 52.8% with an NPV of 93.9%. Neither UFC nor UDA performed well in ruling out bacteriuria in our population. In contrast, both tests ruled out UTI safely and in clinically relevant numbers.

12 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KBKristian Blomberg
Kristian Blomberg
THTorben Hansen
Torben Hansen
CBClaus Lohman Brasen
Claus Lohman Brasen
JMJeppe B. Madsen
Jeppe B. Madsen
LJLars Henrik Jensen
Lars Henrik Jensen
CTCaroline Emilie Brenner Thomsen
Caroline Emilie Brenner Thomsen
The soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS and progression-free survival (PFS) in metastatic CRC (mCRC). It is also the first study to explore the association between the initial change in suPAR level and OS, PFS and the first CT response evaluation. The study included 132 patients with mCRC treated with chemotherapy (FOLFIRI) with or without an EGFR-inhibitor. Blood samples were drawn before the first treatment cycle and in between the first and second treatment cycle. suPAR levels were determined using an ELISA assay. Using the Kaplan-Meyer method, we demonstrated a significantly shorter OS for patients with suPAR levels above the median (HR = 1.79, 95%CI = 1.10–2.92, p = 0.01). We also showed association between plasma suPAR level, gender and performance status (PS). However, we could not show any association with PFS, and analysis on the change in suPAR level provided no significant results. The results showing association between baseline suPAR and OS are in line with previous findings.

20 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MHMathias Amdi Hertz
Mathias Amdi Hertz
IJIsik Somuncu Johansen
Isik Somuncu Johansen
FRFlemming S. Rosenvinge
Flemming S. Rosenvinge
CBClaus Lohman Brasen
Claus Lohman Brasen
EAEline Sandvig Andersen
Eline Sandvig Andersen
HSHelene Skjøt-Arkil
Helene Skjøt-Arkil
Background: Urinary tract infections (UTIs) are a leading bacterial infection in the emergency department (ED). Diagnosing UTIs in the ED can be challenging due to the heterogeneous presentation; therefore, fast and precise tests are needed. We aimed to evaluate the diagnostic precision of procalcitonin (PCT), soluble urokinase plasminogen activator receptors (suPARs), and C-reactive protein (CRP) in diagnosing UTIs, grading the severity of UTIs, and ruling out bacteremia. Methods: We recruited adults admitted to three Danish EDs with suspected UTIs. PCT, suPAR, and CRP were used in index tests, while blood cultures, expert panel diagnosis, and severity grading were used in the reference tests. Logistic regression and area under the receiver operator characteristic curves (AUROCs) were utilized to evaluate the models and determine the optimal cut-offs. Results: We enrolled 229 patients. PCT diagnosed UTI with an AUROC of 0.612, detected severe disease with an AUROC of 0.712, and ruled out bacteremia with an AUROC of 0.777. SuPAR had AUROCs of 0.480, 0.638, and 0.605, while CRP had AUROCs of 0.599, 0.778, and 0.646. Conclusions: The diagnostic performance of PCT, suPAR, or CRP for UTIs or to rule out severe disease was poor. However, PCT can safely rule out bacteremia in clinically relevant numbers in ED patients suspected of UTI.

21 October 2022 in Clinical Biochemistry
Verified
Journal Article
Open access
EAEline Sandvig Andersen
Eline Sandvig Andersen
CØClaus Østergaard
Claus Østergaard
RRRichard Röttger
Richard Röttger
ACAnne Friesgaard Christensen
Anne Friesgaard Christensen
IBIvan Brandslund
Ivan Brandslund
CBClaus Lohman Brasen
Claus Lohman Brasen
Objectives: The aim of this study was to evaluate the logistics and diagnostic performances of dipstick analyses compared to their counterpart central laboratory analyses for detection of bacteriuria, proteinuria, hypergly-cemia, ketosis and hematuria.Design and methods: Urine dipstick results, urine culture results, flow cytometric cell counts, U-albumin-to-creatinine ratio, P-glucose and P-beta-hydroxybutyrate were retrospectively reviewed in a cohort of consecutive patients admitted to the medical emergency departments of two Danish hospitals. Sensitivity, specificity and predictive values of traditional dipstick analysis were estimated and dipstick was compared to flow cytometry for detection of significant bacteriuria using logistic regression. Turn-around-time for central laboratory analyses were assessed.Results: For each comparison, 1,997 patients or more were included. Traditional dipstick analyses for proteinuria, bacteriuria and ketosis reached sensitivities of up to 90%, while sensitivity for hyperglycemia was 59%. Flow cytometry outperformed traditional dipstick analysis for detection of bacteriuria with a difference in the area under the ROC-curve of 0.07. Turn-around-times for 95% delivery of central laboratory analysis results ranged from approximately 11/2 to 2 h. Conclusions: For the detection of bacteriuria and albuminuria, central laboratory analyses reach better perfor-mance than dipstick analysis while achieving acceptable turn-around-times and are thus viable alternatives to dipstick analysis. For detection of ketosis and hyperglycemia, dipstick analysis does not perform adequately, but as very short turn-around-time is often required, these conditions may be best diagnosed by point-of-care blood test rather than dipstick or central laboratory analyses. Dipstick hemoglobin analysis, flow cytometry and microscopic evaluation may serve each their distinct purposes, and thus are relevant in the emergency department.